PCT

Document AL1 Appl. No. 10/773,302

WORLD INTELLECTUAL PROPERTY ORGANIZATION



International Bureau

INTERNACIONAL ARREST	metu	auonai Bureau
INTERNATIONAL APPLICATION PUBLISH	HED (UNDER THE PATENT COOPERATION TREATY (PCI)
The state of the s		(11) T ()
A61K 31/00, 37/00, 31/34, C07D 307/02, C07K 15/00	A1	(42) Endament
		(43) International Publication Date: 15 June 1995 (15.06.95)
(21) International Application Number: PCT/US9	94/1406	
(22) International Filing Date: 7 December 1994 (0	7.12.94	CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data: 08/164,031 8 December 1993 (08.12.93)	U	- I Search report
		With amended claims.
(71) Applicant: PROTOTEK, INC. [US/US]; 6497 Sierra Dublin, CA 94568 (US).	a Lane	,
(72) Inventors: ZIMMERMAN, Mary, P.; 3727 Crofter's Pleasonton, CA 94588 (US). SMITH, Robert, Escondido Circle, Livermore, CA 94550 (US).	Court E.; 574	
(74) Agents: McNETT, John, C. et al.; Woodard, E. Naughton, Moriarty & McNett, Bank One Center/Suite 3700, 111 Monument Circle, Indianapolis, IN (US).	Torres	·
5		

(54) Title: CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS

(57) Abstract

A class of cysteine protease inhibitors which inactivate a cysteine protease by covalently bonding to the protease and releasing a heterocyclic leaving group is presented. The cysteine protease inhibitors of the present invention comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the protease, and a second portion which is attacked by the thiolate anion of the active site of the cysteine protease by providing a carbonyl or carbonyl-equivalent beterocyclic leaving group of the protease inhibitor is of the formula: • O - Het, where Het is a heterocycle having 4-7 atoms in the ring, with at least one of the heterocycle atoms being N, O or S.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	97 t. 1 aa		
ΑÜ	Australia		United Kingdom	MR	Mauritania
BB	Barbados	GE	Georgia	MW	Malawi
BE	Belgium	GN	Guinea	NE	Niger
BF	-	GR	Greece	NL	Netherlands
	Burkina Faso	HŲ	Hungary	NO	Norway
BG	Bulgaria	Œ	freland	NZ	New Zealand
BJ ·	Benin	π	Italy	PL	
BR .	· Brazil	JP	Japan		Poland
BY '	Belarus	KE	Kenya	PT	Portugal
CA.	Canada	KG	Kyrgystan	RO	Romania
CF	Central African Republic	KP		RU	Russian Federation
CG	Congo	•••	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR		SE	Sweden
Cī	Côte d'Ivoire		Republic of Korea	SI	Slovenia
CM	Сапистооп	KZ	Kazakhstan	SK	Slovakia
CN	China	ഥ	Liectrenstein	SN	Senegal
cs	Czechoslovakia	LK	Sri Lanka	TD	Chad
cz		LU	Luxembourg	TG	Togo
	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	11	•
DK	Denmark	MD -	Republic of Moldova	UA	Trinidad and Tobago
ES	Spain	MG	Madagascar		Ukraine
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon		14100Rotte	VN	Vict Nam

CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS

FIELD OF THE INVENTION

The present invention relates generally to cysteine

protease inhibitors, and more particularly to cysteine
protease inhibitors which are reptidyl ketones having
heterocyclic leaving groups. The cysteine protease
inhibitors of the present invention are particularly designed
for the in vivo management of cysteine proteases,

10 particularly cathepsins B, L, H and C, and their primitive enzymatic counterparts.

BACKGROUND TO THE INVENTION

Cysteine proteases associated with human disease states can be grouped into three categories: (1) lysosomal 15 cathepsins; (2) cytosolic calpains; and (3) procaryotic enzymes with autocatalytic activation. Cathepsins B, H, and L are cysteinyl proteases involved in normal protein degradation. As such, they are generally located in the lysosomes of cells. When these enzymes are found 20 extralysosomaly they have been implicated by use of synthetic substrate technology and by natural endogenous inhibitors as playing a causative role in a number of disease states such as rheumatoid arthritis, osteo arthritis, pneumocystis carinii, schistosomiasis, trypanosoma cruzi, trypanosoma 25 brucei brucei, Crithidia fusiculata, malaria, periodontal disease, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, etc. For example, a connection between cathepsin B-type enzymes and rheumatoid arthritis has been

suggested in van Noorden and Everts, "Selective Inhibition of Cysteine Proteinases by Z-Phe-Ala-CH₂F Suppresses Digestion of Collagen by Fibroblasts and Osteoclasts, " 178 Biochemical and Biophysical Research Communications 178; Rifkin, 5 Vernillo, Kleekner, Auszmann, Rosenberg and Zimmerman, "Cathepsin B and L Activities in Isolated Osteoclasts," 179 Biochemical and Biophysical Research Communications 63; Grinde, "The Thiol Proteinase Inhibitors, Z-Phe-Phe-CHN₂ and Z-Phe-Ala-CHN2, Inhibit Lysosomal Protein Degradation 10 in Isolated Rat Hepatocytes, 757 Biochimica et Biophysica Acta 15; Mason, Bartholomew and Hardwick, "The Use of Benzyloxycarbonyl[125 I]iodotyrosylalanyldiazomethane as a Probe for Active Cysteine Proteinases in Human Tissues," 263 Biochem. J. 945; van Noorden, Smith and Rasnick, "Cysteine 15 Proteinase Activity in Arthritic Rat Knee Joints and the Effects of a Selective Systemic Inhibitor, Z-Phe-Ala-CH₂F," 15 J. Rheumatol. 1525; and van Noorden, Vogels and Smith, "Localization and Cytophotometric Analysis of Cathepsin B Activity in Unfixed and Undecalified Cryostat Sections of 20 Whole Rat Knee Joints," 37 J. Histochemistry and Cytochemistry 617. A connection between cathepsin B and osteo arthritis has been suggested in Delaissé, Eeckhout and Vaes, "In Vivo and In Vitro Evidence for the Involvement of Cysteine Proteinases in Bone Resorption," 125 Biochemical and 25 Biophysical Research Communications 441; a connection between cathepsin B and pneumocystis carinii has been suggested in Hayes, Stubberfield, McBride and Wilson, "Alterations in Cysteine Proteinase Content of Rat Lung Associated with Development of Pneumocystis Carinii Infection, " 59 Infection 30 and Immunity 3581; a connection between cysteine proteinases and schistosomiasis has been suggested in Cohen, Gregoret, Amiri, Aldape, Railey and McKerrow, "Arresting Tissue Invasion of a Parasite by Protease Inhibitors Chosen With the Aid of Computer Modeling, " 30 Biochemistry 11221. A

35 connection between cysteine proteinases and trypanosoma

cruzi, trypanosoma brucei brucei and crithidia fasciculata has been suggested in Ashall, Harris, Roberts, Healy and Shaw, "Substrate Specificity and Inhibitor Sensitivity of a Trypanosomatid Alkaline Peptidase," 1035 Biochimica et

- 5 Biophysica Acta 293, and/or in Ashall, Angliker and Shaw, "Lysis of Trypanosomes by Peptidyl Fluoromethyl Ketones," 170 Biochemical and Biophysical Research Communications 923. A connection between cysteine proteinases and malaria has been suggested in Rosenthal, Wollish, Palmer and Rasnick,
- 10 "Antimalarial Effects of Peptide Inhibitors of a Plasmodium Falciparum Cysteine Proteinase, 88 <u>J. Clin. Invest.</u> 1467, and in Rosenthal, Lee and Smith, "Inhibition of a Plasmodium Vinckei Cysteine Proteinase Cures Murine Malaria," (in press). A connection between cathepsin B and tumor
- 15 metathesis has been suggested in Smith, Rasnick, Burdick, Cho, Rose and Vahratian, "Visualization of Time-Dependent Inactivation of Human Tumor Cathepsin B Isozymes by a Peptidyl Fluoromethyl Ketone Using a Fluorescent Print Technique, 8 Anti-cancer Research 525. A connection between
- 20 cathepsin B and cancer has been suggested in Gordon and Mourad, 2 Blood Coagulation and Fibrinolysis 735. A connection between cathepsin B and periodontal disease has been suggested in Cox, Cho, Eley and Smith, "A Simple, Combined Fluorogenic and Chromogenic Method for the Assay of
- 25 Proteases in Gingival Crevicular Fluid, " 25 J. Periodont. Res. 164; Uitto, Larjava, Heino and Sorsa, "A Protease of Bacteroides Gingivalis Degrades Cell Surface and Matrix Glycoproteins of Cultured Gingival Fibroblasts and Induces Secretion of Collagenase and Plasminogen Activator," 57
- 30 <u>Infection and Immunity</u> 213; Kunimatsu, Yamamoto, Ichimaru, Kato and Kato, "Cathepsins B, H and L Activities in Gingival Crevicular Fluid From Chronic Adult Periodontitis Patients and Experimental Gingivitis Subjects," 25 J Periodont Res 69; Beighton, Radford and Naylor, "Protease Activity in Gingival
- 35 Crevicular Fluid From Discrete Periodontal Sites in Humans

With Periodontitis or Gingivitis"; 35 Archs oral Biol. 329; Cox and Eley, "Preliminary Studies on Cysteine and Serine Proteinase Activities in Inflamed Human Gingiva Using Different 7-Amino-4-Trifluoromethyl Coumarin Substrates and 5 Protease Inhibitors," 32 Archs oral Biol. 599; and Eisenhauer, Hutchinson, Javed and McDonald, "Identification of a Cathepsin B-Like Protease in the Crevicular Fluid of Gingivitis Patients," 62 J Dent Res 917. A connection between cathepsin B and metachromatic leukodystrophy has been 10 suggested in von Figura, Steckel, Conary, Hasilik and Shaw, "Heterogeneity in Late-Onset Metachromatic Leukodystrophy. Effect of Inhibitors of Cysteine Proteinases," 39 Am J Hum Genet. 371; a connection between cathepsin B and muscular leukodystrophy has been suggested in Valentine, Winand, 15 Pradhan, Moise, de Lahunta, Kornegay and Cooper, "Canine X-Linked Muscular Dystrophy as an Animal Model of Duchenne Muscular Dystrophy: A Review, " 42 Am J Hum Genet 352; a connection between cathepsin B and rhinovirus has been suggested in Knott, Orr, Montgomery, Sullivan and Weston, 20 "The Expression and Purification of Human Rhinovirus Protease 3C, " 182 Eur. J. Biochem. 547; a connection between cathepsin B and kidney disease has been suggested in Baricos, O'Connor, Cortez, Wu and Shah, "The Cysteine Proteinase Inhibitor, E-64, Reduces Proteinuria in an Experimental Model of 25 Glomerulonephritis," 155 <u>Biochemical and Biophysical Research</u> Communications 1318; and a connection between cathepsin B and multiple sclerosis has been suggested in Dahlman, Rutschmann, Kuehn and Reinauer, "Activation of the Multicatalytic Proteinase from Rat Skeletal Muscle by Fatty Acids or Sodium 30 Dodecyl Sulphate, 228 Biochem. J. 171.

Connections between certain disease states and cathepsins H and C have also been established. For example, cathepsin H has been directly linked to the causative agents of Pneumocystis carinii and in the neuromuscular diseases

35 Duchenne dystrophy, polymyositis, and neurogenic disorders.

Stauber, Riggs and Schochet, "Fluorescent Protease Histochemistry in Neuromuscular Disease," Neurology 194 (Suppl. 1) March 1984; Stauber, Schochet, Riggs, Gutmann and Crosby, "Nemaline Rod Myopathy: Evidence for a Protease

- 5 Deficiency," <u>Neurology</u> 34 (Suppl. 1) March 1984. cathepsin C has been directly linked to muscular diseases such as nemaline myopathy, to viral infections, and to processing and activation of bone marrow serine proteases (elastase and granzyme A). McGuire, Lipsky and Thiele,
- 10 "Generation of Active Myeloid and Lymphod Granule Serine Proteases Requires Processing by the Granule Thiol Protease Dipeptidyl Peptidase I, 268 J. Biol. Chem. 2458-67; L. Polgar, Mechanisms of Protease Action (1989); Brown, McGuire and Thiele, "Dipeptidyl Peptidase I is Enriched in Granules
- 15 of In Vitro- and In Vivo-Activated Cytotoxic T Lymphocytes," 150 Immunology 4733-42. The Brown et al. study effectively demonstrated the feasibility of inhibiting cathepsin C (DPP-I) in the presence of other cysteinyl enzymes based on. substrate specificity. Unfortunately, the diazoketones used
- 20 in that study are believed to be mutagenic and not appropriate for in vivo application.

The cytosolic or membrane-bound cysteine proteases called calpains have also been implicated in a number of disease states. For example, calpain inhibitor can be useful for the

- 25 treatment of muscular disease such as muscular dystrophy, amyotrophy or the like, 25 Taisha (Metabolism) 183 (1988); 10 J. Pharm. Dynamics 678 (1987); for the treatment of ischemic diseases such as cardiac infarction, stroke and the like, 312 New Eng. J. Med. 159 (1985); 43 Salshin Igaku 783
- 30 (1988); 36 Arzneimittel Forschung/Drug Research 190, 671 (1986); 526 Brain Research 177 (1990); for improving the consciousness disturbance or motor disturbance caused by brain trauma, 16 Neurochemical Research 483 (1991); 65 J. Neurosurgery 92 (1986); for the treatment of diseases caused
- 35 by the demyelination of neurocytes such as multiple

sclerosis, peripheral nervous neuropathy and the like, 47 J. Neuochemistry 1007 (1986); and for the treatment of cataracts, 28 Investigative Ophthalmology & Visual Science 1702 (1987); 34 Experimental Eye Research 413 (1982); 6 Lens and Eye Toxicity Research 725 (1989): 32 Investigative Ophthalmology & Visual Science 533 (1991).

Calpain inhibitors may also be used as therapeutic agents for fulminant hepatitis, as inhibitors against aggregation of platelet caused by thrombin, 57 Thrombosis Research 847

10 (1990); and as a therapeutic agent for diseases such as breast carcinoma, prostatic carcinoma or prostatomegaly, which are suspected of being caused by an abnormal activation of the sex hormone receptors.

Certain protease inhibitors have also been associated with Alzheimer's disease. See, e.g., 11 Scientific American 40 (1991). Further, thiol protease inhibitors are believed to be useful as anti-inflammatory drugs, 263 J. Biological Chem. 1915 (1988); 98 J. Biochem. 87 (1985); as antiallergic drugs, 42 J. Antibiotics 1362 (1989); and to prevent the metastasis of cancer, 57 Seikagaku 1202 (1985); ___ Tumor Progression and Markers 47 (1982); and 256 J. Biological Chemistry 8536 (1984).

Further, cysteine protease has been shown to process the convertase enzyme of interleukin-1, a cytokine that is

25 implicated in septic shock, wound healing, and the growth of certain leukemias. See, e.g., Thornberry et al., 356 Nature 755; Goll et al., 74 Biochimi 225 (1992), and Bioworld Today, Vol. 3, No. 67, p. 1, April 3, 1992.

Although a number of cysteine proteinase inhibitors have

30 been identified, most of these have drawbacks for in vivo
use. In particular, drawbacks such as reversibility of
inhibition, lack of specificity, and rapid clearance from the
body have been associated with prior art inhibitors. The
microbial products antipain and leupeptin, for example, are
35 effective but reversible inhibitors of cysteine proteinase

(McConnell et al., 33 <u>J. Med. Chem.</u> 86-93; Sutherland et al. 110 <u>Biochem. Biophys. Res. Commun.</u> 332-38), and also inhibit certain serine proteinases (Umezawa, 45 <u>Meth. Enzymol.</u> 678-95). The compound E64 and its synthetic analogues are more selective inhibitors (<u>see</u>, <u>e.g.</u>, Barret et al., 201 <u>Biochem. J.</u> 189-98, and Grinde, 701 <u>Biochem. Biophys. Acta.</u> 328-33), but disappear too quickly from the circulation for in vivo use (Hashida et al. 91 <u>J. Biochem.</u> 1373-80).

To date, two classes of peptidyl ketone inhibitors have been identified. One class, originally described by Abeles, comprises reversible inhibitors of both serine and cysteine proteases. For example, Abeles et al. describe trifluoromethyl ketones of the form:

15 Abeles et al., "Fluoroketone Inhibitors of Hydrolytic Enzymes," 24 <u>Biochemistry</u> 1813-17, (1985).

Similarly, reversible inhibitors to serine proteases also exist in their hydrated form:

20

and therefore become transition state analog inhibitors. Further, Hu et al., "Inhibition of Cathepsin B and Papain by Peptidyl α-ketoEsters, α-ketoAmides, α-Diketones, and α-ketoAcids", 281 Archives of Biochemistry and Biophysics 271-274 (1990) describe compounds of similar reactivity of the form:

30 R=CO₂H, CO₂Me, C-NEt, C-LeuOMe, and COBu

Most recently, European Patent publication EPO-525420-Al disclosed peptidyl ketones that were activated by the permanent (nonfissionable) placement of methylthiomethyl ring or amine, thus making reversible inhibitors of reduced 5 efficacy.

The difference between these noncleavable reversible inhibitors and the irreversible inhibitors of the present invention is that the former inhibitors remain intact in the active site constantly partitioning with the external medium while the latter cleaves and leaves the peptide portion irreversibly bonded to the enzymes active site, thereby permanently disabling the enzyme. This latter mechanism translates into lower required doses of therapeutic agent.

The most promising type of cysteine proteinase inhibitors have an activated carbonyl with a suitable α -leaving group fused to a programmed peptide sequence that specifically directs the inhibitor to the active site of the targeted enzyme. Once inside the active site, the inhibitor carbonyl is attacked by a cysteine thiolate anion to give the resulting hemiacetal, which collapses via a 1,2-thermal migration of the thiolate and subsequent displacement of the α -keto-leaving group. The bond between enzyme and inhibitor is then permanent and the enzyme is irreversibly inactivated.

The usefulness of an inhibitor in inactivating a particular enzyme therefore depends not only on the "lock and key" fit of the peptide portion, but also on the reactivity of the bond holding the α-leaving group to the rest of the inhibitor. It is important that the leaving group be reactive only to the intramolecular displacement via a 1,2-migration of sulfur in the breakdown of the hemithioacetal intermediate.

Groundbreaking work regarding cysteine proteinase inhibitors having an activated carbonyl, a suitable

α-leaving group and a peptide sequence that effectively and specifically directs the inhibitor to the active site of the targeted enzyme was disclosed in U.S. Patent 4,518,528 to Rasnick, incorporated herein by reference. That patent established peptidyl fluoromethyl ketones to be unprecedented inhibitors of cysteine proteinase in selectivity and effectiveness. The fluoromethyl ketones described and synthesized by Rasnick included those of the formula:

10 $X--Y_{n}-N$ C $CHF--R_{2}$

wherein R₁ and R₂ are independently selected from the group hydrogen, alkyl of 1-6 carbons, substituted alkyl of 1-6 carbons, aryl, and alkylaryl where the alkyl group is of 1-4 carbons; n is an integer from 1-4 inclusive; X is a peptide end-blocking group; and Y is an amino acid or peptide chain of from 1-6 amino acids.

Peptidylketone inhibitors using a phenol leaving group
20 are similar to the peptidyl fluoroketones. As is known in
the art, oxygen most closely approaches fluorine in size and
electronegativity. Further, when oxygen is bonded to an
aromatic ring these values of electronegativity become even
closer due to the electron withdrawing effect of the sp²
25 carbons. The inductive effect of an α-ketophenol versus an
α-ketofluoride when measured by the pka of the
α-hydrogen, appears comparable within experimental error.

Unfortunately, the leaving groups of prior art cysteine protease inhibitors have presented problems of toxicity,

30 solubility, etc. For example, the inhibitors disclosed by Krantz et al. in U.S. Patent No. 5,055,451 have been found to be unacceptably toxic when introduced into animals such as

rabbits or dogs.

A need therefore exists for cysteine protease inhibitors with improved solubility and toxicity profiles, and which are particularly suitable for <u>in vivo</u> use. The present invention addresses that need.

SUMMARY OF THE INVENTION

Briefly describing the present invention, there is provided a class of cysteine protease inhibitors which deactivates the protease by covalently bonding to the cysteine protease and releasing a heterocyclic leaving group. The cysteine protease inhibitors of the present invention accordingly comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the

- 10 protease, and a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a heterocyclic
- 15 leaving group. The heterocyclic leaving group of the protease inhibitor is of the formula: O Het, where Het is a heterocycle having 4-7 members in the ring, with at least one of the heterocycle members being N, O or S.

One object of the present invention is to provide 20 improved cysteine protease inhibitors with improved solubility and toxicity profiles.

A further object of the present invention is to provide a class of cysteine protease inhibitors which are particularly effective for <u>in vivo</u> applications.

25 Further objects and advantages of the present invention will be apparent from the following description.

DESCRIPTION OF THE PREFERRED EMBODIMENT

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications of the invention, and such further applications of the principles of the invention as illustrated herein, being contemplated as would normally occur to one skilled in the art to which the invention relates.

As indicated above, the present invention relates to cysteine protease inhibitors which contain heterocyclic leaving groups. In one aspect of the invention, a group of cysteine protease inhibitors which have been shown to be particularly effective for <u>in vivo</u> applications is disclosed.

The cysteine protease inhibitors described herein function as the sum of two portions. The first portion ²⁰ defines the specificity of a particular inhibitor to an enzyme by the spacial, hydrophobic or hydrophilic and ionic interactions of a particular composition that either imitates or improves upon the nature of the enzyme's natural substrate. The second portion is a trap that covalently 25 binds the enzyme in a two-step mechanism: the first step involves the nucleophilic attack of the enzyme thiolate on the carbonyl of the inhibitor to form a hemithioketal. then energetically favorable for this intermediate to undergo a 1,2 migration of the thiolate in which a heterocyclic $^{
m 30}$ leaving group is simultaneously released. The enzyme has now become irreversibly bonded to the inhibitor. With the inhibitors of the present invention the leaving group is a heterocyclic leaving group.

Accordingly, the cysteine proteinase inhibitors of the

present invention are preferably constructed with an activated carbonyl which bears a suitable α -leaving group which is fused to a programmed peptide sequence that specifically directs the inhibitor to the active site of the 5 targeted enzyme. (For example, Z-Phe-PheCHN, preferentially inhibits cathepsin L over cathepsin B.) Once inside the active site, this inhibitor carbonyl is attacked by a cysteine thiolate anion to give the resulting hemiacetal form. If the α -leaving group then breaks off, the bond 10 between enzyme and inhibitor becomes permanent and the enzyme is irreversibly inactivated. The selectivity of the inhibitor for a particular enzyme depends not only on the "lock and key" fit of the peptide portion, but also on the reactivity of the bond binding the leaving group to the rest 15 of the inhibitor. It is very important that the leaving group must be reactive only to the intramolecular displacement via a 1,2-migration of sulfur in the breakdown of the hemithioacetal intermediate. The mechanism of protease inhibition is shown below in FIG. 1.

Peptide-C-CH₂-O-Het \rightarrow Peptide-C-CH₂-O-Het \rightarrow

Peptide-C-CH₂SEnz + HO-Het

The preferred inhibitors of the present invention can be 25 described generally by the formula:

wherein B is an amino acid blocking group for the N-terminal amino acid, each $(P)_{x}$ is an optionally protected α -amino acid residue, x is an integer between zero and 5, inclusive, and Het is the heterocyclic portion of the leaving group.

As is conventional in the art, and as used herein, amino acid residues may be designated as P_1 , P_2 , etc., wherein

 P_1 refers to the amino acid residue nearest the leaving group, P_2 refers to the amino acid residue next to P_1 and nearer the blocking group, etc. In dipeptide inhibitors therefore, P_2 is the amino acid residue nearest the blocking group.

More specifically, the compounds employed in the present invention are of the formula:

$$B-(R_3)_{n}-(R_2)_{m}-NH-CH-C-CH_2-O-Het$$

wherein

10

B is H or an amino acid blocking group for an N-terminal amino acid nitrogen;

 ${\bf R_1}$ is the amino acid side chain of the ${\bf P_1}$ amino acid residue;

 $\rm R_2$ is the amino acid residue of the $\rm P_2$ amino acid; $\rm R_3$ is the amino acid residue of the $\rm P_3$ amino acid; n is 0 or 1;

m is 0 or 1; and

Het is the heterocyclic portion of the leaving group; wherein the heterocyclic leaving group includes a four-, five-, six- or seven-membered ring having at least one C and at least one of N, O or S in the ring.

Concerning the amino acid blocking group B for the

N-terminal amino acid nitrogen, many suitable peptide
end-blocking groups are known in the art. For example the
end-blocking groups identified in E. Gross and J. Meienhofer
(eds.), The Peptides, Vol. 3 are generally suitable for use
in the present invention. Preferred blocking groups include

N-morpholine carbonyl and derivatives of propionic acid
derivatives that have intrinsic analgesic or
anti-inflammatory action. Examples of blocking groups having
intrinsic analgesic or anti-inflammatory action may be found
in Gilman, Goodman, Gilman, The Pharmacological Basis of

35 Therapeutics, Sixth Ed. MacMillan, Chapter 29. As defined

herein, the peptide end-blocking group is attached to either an amino acid or a peptide chain.

One particularly effective blocking group is the 4-morpholinylcarbonyl ("Mu") blocking group shown below:

4-morpholinylcarbonyl

The peptide portion of the inhibitor may include any 10 peptide appropriate for targetting a desired cysteine protease. Preferably, the side chain on the \mathbf{P}_1 amino acid is selected according to the enzyme being targetted. cathepsin B or L, this might include side chains such that the linked P_1 amino acid is a member of the group 15 consisting of alanyl (Ala), arginyl (Arg), aspartic acid (Asp), glutamic acid (Glu), histidyl (His), homophenylalanyl (HPhe), phenylalanyl (Phe), ornithyl (Orn), seryl (Ser) and threonyl (Thr), and optionally substituted analogues thereof such as thiazoles and amino thiazoles. Preferably the side 20 chain on the P_2 amino acid is selected so that the linked P₂ amino acid is a member of the group consisting of phenylalanyl (Phe), leucyl (Leu), tyrosyl (Tyr) and valyl (Val) amino acid residues and substituted analogues thereof, particularly including Tyr(OMe).

As indicated above, each of the cysteine protease inhibitors of the present invention includes a heterocyclic leaving group. The heterocycle of the leaving group is a ring of variable size (4-7 members) containing one or more heteroatoms and n double bonds where n = 0-3. This ring is bonded through an oxygen atom which becomes part of the leaving group during inhibition of the targeted enzyme. In the absence of the targeted active site, the inhibitor construction is an ether that is very stable in the physiological environments of the stomach, lysosome, or

disease state arthritic joint.

The heterocycles of the present invention may be derived from the group that includes pyridine n-oxides, uracils, cytosines, pyrones, pyridones, pyrimidines, pyrazines, furans, thiophenes, pyrroles, oxazoles, thiazoles, pyrazoles, imidazoles, triazoles, tetrazoles and their optionally-substituted derivatives such as benzo-fused derivatives. For oral bioavailability, the most preferred leaving groups have at least one heteroatom for each four carbon atoms in the leaving group.

The ability of the leaving group to protonate at physiological pH is directly related to its inability to cross cell membranes which can be advantageous in certain applications. In the same context, the ability of a heterocycle to chelate with a metal ion may (1) impede crossing of membranes and/or (2) target metalloproteases such as calpains. In the environment of the active site protonation and/or hydrogen bonding of ring heteroatoms will accentuate its role as a leaving group.

It is to be appreciated that the heterocycle may be chosen specifically in accord with the function of the enzyme to be inhibited. For example, the inhibitor would use a derivative of hydroxyproline (a major constituent of collagen) to target a collagenase:

B-
$$(R_3)_n$$
- $(R_2)_{10}$ NH-CHC-CII₂-O-CO₂Me

or the natural substrate (hydroxyproline) may be improved upon by a suitable replacement such as a hydroxyfuran which upon displacement from the inhibitor can and does tautomerize to a more stable keto form increasing its efficiency as a leaving group.

It is also to be appreciated that during the course of the reaction of enzyme with inhibitor, the carbonyl of the inhibitor rehybridizes to sp3 and forms a ketal intermediate with the thiol function of the enzyme. Under the acid 5 conditions of this reaction, other ketals can exchange with this intermediate either by going through the ketone or by ketal-ketal exchange. Accordingly, ketals can be substituted for carbonyls in the peptidyl inhibitors of the present invention. Similarly, other compounds such as hydrazones, 10 hemiketals, oximes, imines, cyanohydrins, enolethers, enamines, hemithioketals, and the like are to be considered carbonyl equivalents and may be substituted for a carbonyl or to give a carbonyl under the acidic conditions of these inhibition reactions. Utilization of such derivatives can 15 also be vehicles to either improve the bioavailability of the inhibitor drug or keep it from crossing a cellular membrane depending upon the hydrophobic nature of the masking function.

Finally, it is to be appreciated that the development and synthesis of compounds having isosteric replacements of amide 20 bonds is now a standard practice in the development of biologically active peptides once the optimum peptide sequence has been identified. Accordingly, the present invention includes compounds having one or more modified amide bonds in the peptide sequence so long as conformation 25 and binding are maintained while secondary enzymatic hydrolysis is prevented. For a list of such modifications see Kaltenbronn, 33, J. Med. Chem., 838. In addition, inhibitors having a hydrazine replacement for the Pl nitrogen as reported by Giordano for other halogen methyl 30 ketones are also intended to be claimed.

Reference will now be made to specific examples using the processes described above. It is to be understood that the examples are provided to more completely describe preferred

5

embodiments, and that no limitation to the scope of the invention is intended thereby.

EXAMPLE 1

Synthesis of Mu-Phe-HPhe-CH₂-O-

In a 100 ml round bottom flask equipped with an argon line was placed Mu-Phe-HPhe-Br (1.0 g, 1.94 mmol), potassium fluoride (449.5 mg, 7.75 mmol), potassium carbonate (534.9 mg, 3.87 mmol)-K CO was added to a second to the sec

- mg, 3.87 mmol)-K₂CO₃ was added to control the acidic environment, and 4-hydroxy-6-methyl-2-pyrone (488.0 mg, 3.87 mmol). About 5 ml of DMF was added to dissolve the solid mixture. The reaction flask was immersed in a 50°C oil bath. The reaction was allowed to run for 40 minutes in
- order to ensure the completion of the reaction. The reaction mixture was diluted with ethyl acetate, and potassium fluoride was removed by a small silican gel column. The solvent ethyl acetate was stripped by a water vacuum pump, and DMF was removed by an oil vacuum pump. The next day the
- 20 light yellow product was recrystallized in hexane:diethyl ether (50%:50%). The white precipitate was filtered and a NMR spectrum was obtained. m.p. 94-98°C.

EXAMPLE 2

25 Synthesis of Mu-Phe-HPhe-CH₂-O-CH₂

In a 100 ml round bottom flask equipped with an argon line was placed Mu-Phe-HPhe-Br (300 mg, 0.581 mmol), potassium fluoride (134.8 mg, 2.33 mmol), potassium carbonate

30 (321.4 mg, 2.33 mmol)-K₂CO₃ was added to control the acidic environment, and 5,6-dilydro-4-hydroxy-6-methyl-2H-pyran-2-one (298.0 mg, 2.33 mmol). About 5 ml of DMF was added to dissolve the solid mixture. The reaction flask was immersed in a 50°C 0il

bath. The reaction was allowed to run for 40 minutes in order to ensure the completion of the reaction. The reaction mixture was diluted with ethyl acetate, and potassium fluoride was removed by a small silica gel column. The solvent ethyl acetate was removed by a water vacuum pump, and DMF was removed by an oil vacuum pump. The next day the light yellow product was recrystallized in 50:50 hexane:diethyl ether. The white precipitate was filtered and a NMR spectrum was obtained. m.p. 74-78°C.

10

EXAMPLE 3

Synthesis of Mu-Phe-HPhe-CH₂-O-V-O-CH₂

In a 100 ml round bottom flask equipped with an argon 15 line was placed Mu-Phe-HPhe-Br (1 g, 1.94 mmol), potassium fluoride (0.45 g, 7.75 mmol), potassium carbonate (1.07 g, 7.75 μ mol)- K_2^{CO} was added to control the acidic environment, and 2-hydroxy-3-methylcarboxypyridine (0.59 g, 3.87 mmol). About 5 ml of DMF was added to dissolve the 20 solid mixture. The reaction flask was immersed in a 50°C oil The reaction was allowed to run for 40 minutes in order to ensure the completion of the reaction. mixture was diluted with ethyl acetate, and potassium fluoride was removed by a small silica gel column. 25 solvent ethyl acetate was removed by a water vacuum pump, and DMF was removed by an oil vacuum pump. The next day the light yellow product was recrystallized in 50:50 hexane: diethyl ether. The white precipitate was filtered and a NMR spectrum was obtained. m.p. 100-102°C.

30

EXAMPLE 4

In a 100 ml round bottom flask equipped with an argon line was placed Mu-Phe-HPhe-Br (500 mg, 0.969 mmol), potassium fluoride (224.8 mg, 3.876 mmol), potassium carbonate (267.8 mg, 1.938 mmol)- K_2CO_3 was added to 5 control the acidic environment, and 3-hydroxypyridine (184.3 mg, 1.938 mmol). About 5 ml of DMF was added to dissolve the solid mixture. The reaction flask was immersed in a 50°C oil The reaction was allowed to run for 40 minutes in order to ensure the completion of the reaction. The reaction 10 mixture was diluted with ethyl acetate, and potassium fluoride was removed by a small silica gel column. solvent ethyl acetate was removed by a water vacuum pump, and DMF was removed by an oil vacuum pump. The next day the light yellow product was recrystallized in 50:50 15 hexane: diethyl ether. The white precipitate was filtered and a NMR spectrum was obtained. m.p. 112-115°C.

EXAMPLE 5

Synthesis of Mu-Phe-HPhe-CH2-O-

In a 100 ml round bottom flask equipped with an argon

line was placed Mu-Phe-HPhe-Br (300 mg, 0.581 mmol),
potassium fluoride (135.1 mg, 2.33 mmol), potassium carbonate
(322.0 mg, 2.33 mmol)-K₂CO₃ was added to control the
acidic environment, and 2-hydroxypyrimidine (111.7 mg, 1.938
mmol). About 5 ml of DMF was added to dissolve the solid
mixture. The reaction flask was immersed in a 50°C oil
bath. The reaction was allowed to run for 40 minutes in
order to ensure the completion of the reaction. The reaction
mixture was diluted with ethyl acetate, and potassium
fluoride was removed by a small silica gel column. The
solvent ethyl acetate was removed by a water vacuum pump, and
DMF was removed by an oil vacuum pump. The next day the
light yellow product was recrystallized in 50:50

hexane:diethyl ether. The white precipitate was filtered and a NMR spectrum was obtained. m.p. 95-100°C.

EXAMPLE 6

Synthesis of Mu-Phe-IIPhe-Cli₂-0-

- In a 100 ml round bottom flask equipped with an argon line was placed Mu-Phe-HPhe-CH₂-Br (500 mg, 0.969 mmol), potassium fluoride (224.8 mg, 3.876 mmol), potassium carbonate (535.7 mg, 3.876 mmol)-K₂CO₃ was added to control the acidic environment, and 2-furanone (275 μl, 3.876 mmol). About 5 ml of DMF was added to dissolve the solid mixture. The reaction flask was immersed in a force
- solid mixture. The reaction flask was immersed in a 50°C oil bath. The reaction was allowed to run for 40 minutes in order to ensure the completion of the reaction. The reaction mixture was diluted with ethyl acetate, and potassium
- 15 fluoride was removed by a small silica gel column. The solvent ethyl acetate was removed by a water vacuum pump, and DMF was removed by an oil vacuum pump. The next day the light yellow product was recrystallized in 50:50 hexane:diethyl ether. The white precipitate was filtered and
- 20 a NMR spectrum was obtained. m.p. 90-93°C.

EXAMPLE 7

Synthesis of Mu-Phe-HPhe-CH₂-0-

In a 100 ml round bottom flask equipped with an argon line was placed Mu-Phe-HPhe-Br (200 mg, 0.388 mmol), potassium fluoride (89.9 mg, 1.55 mmol), potassium carbonate (214.3 mg, 1.55 mmol)-K₂CO₃ was added to control the acidic environment, and 2-hydroxypyrimidine (205.5 mg, 1.55 mmol). About 4 ml of DMF was added to dissolve the solid mixture. The reaction flask was immersed in a 50°C oil bath. The reaction was allowed to run for 40 minutes in

order to ensure the completion of the reaction. The reaction mixture was diluted with ethyl acetate, and potassium fluoride was removed by a small silica gel column. The solvent ethyl acetate was removed by a water vacuum pump, and 5 DMF was removed by an oil vacuum pump. The next day the light yellow product was recrystallized in 50:50 hexane:diethyl ether. The white precipitate was filtered and a NMR spectrum was obtained. m.p. 82-85°C.

EXAMPLES 8-9

10 Synthesis of Mu-Phe-IIPhe-CII₂-O-CO₂CH₃
(MuPheHPhe-O-

(proline methyl ester)).

In a 100 ml round bottom flask equipped with an argon 15 line was placed Mu-Phe-HPhe-Br (500 mg, 0.969 mmol), potassium fluoride (224.8 mg, 3.876 mmol), potassium carbonate (535.7 mg, 3.876 mmol) was added to control the acidic environment, and Boc-L-hydroxyproline-methylester (475.2 mg, 1.938 mmol). About 6 ml of DMF was added to 20 dissolve the solid mixture. The reaction was left at the room temperature and periodical TLC was checked to monitor the progress of the reaction. According to TLC, the reaction was completed after about one hour. The reaction mixture was diluted with ethyl acetate, and potassium fluoride was 25 removed by a short silica gel column. The solvent ethyl acetate was stripped by a water vacuum pump, and DMF was removed by an oil vacuum pump. The product was dried under the vacuum pump. The next day the light yellow oily product was recrystallized in hexane. The precipitate was filtered 30 and a NMR spectrum was obtained.

De-Boc: About 5 ml of methylene chloride was used to dissolve 100 mg of the Boc product. Then about 5 ml of HCl. Dioxane was put into the 50 ml flask, and the reaction was

allowed to proceed for about 45 minutes under argon. Carbon dioxide was released from the flask; bubbles came up to the surface of the reaction mixture. After the completion of the reaction, the mixture was slowly dropped into six test tubes filled with diethyl ether. The precipitation came out and was allowed to continue for about half hour. The product was quickly removed through suction filtration and it was put in a dry box overnight.

EXAMPLE 10

Synthesis of Mu-Phe-HPhe-CH₂-O-CH₂CH₃.

In a 100 ml round bottom flask equipped with an argon line was placed Mu-Phe-HPhe-CH₂-Br (300 mg, 0.582 mmol), potassium fluoride (150 mg, 2.4 mmol), and potassium carbonate (150 mg, 1.2 mmol), and 8 ml of 200 proof ethanol.

The reaction was stirred 3 hours, filtered and the solvents were removed under vacuum and the residue chromatographed on a short silica gel column (CHCl₃:MEOH 95:5) and then recrystallized from ether.

EXAMPLE 11

20 General Procedure for the Preparation of HC1-HPhe-CH2-O-Substituted Heterocyclic Inhibitors

(a) BOC-HPhe diazoketone

To BOC homophenylalanine (18 mmol) in 150 ml distilled THF at -20°C was added one equivalent of N-methylmorpholine followed by one equivalent of isobutylchloroformate. After 10 minutes, the mixture was poured through filter paper into 200 ml etheral solution of diazomethane which was made according to the suppliers directions from 8.6 g of Diazald (Aldrich). The reaction was allowed to stir overnight, and then poured into 100 ml water. The organic portion was

washed with NaHCO3(aq) (2X50 ml), brine (2X50 ml); dried over $MgSO_4$; concentrated to give the diazoketone 5.38 g (99%) of a yellow oil that crystalizes on standing.

(b) BOC-HPhe-CH2Br

To the above diazoketone (5.38 g, 0.018 mol) in 20 ml of methylene chloride at -5°C is added dropwise 30% HBr in acetic acid which is diluted three-fold with methylene chloride. The addition is made at a rate that allows the monitoring of the evolved nitrogen and until all yellow color of the starting material has disappeared. The reaction is poured into 50 ml water and diluted with another 100 ml of methylene chloride. The organic layer is separated, washed with NaIICO₃ (aq) (50 ml), brine (50 ml), dried over MgSO₄ and concentrated to give a white solid which is characterized by its NMR.

(c) <u>BOC-HPhe-CH2-O-Substituted Heterocycle</u>

In a 100 ml round bottom flask equipped with an argon line was placed BOC-HPhe-CH₂Br (1.4 mmol), potassium fluoride (5.6 mmol) and the substituted phenol (5.6 mmol).

20 About 1 ml of DMF is added and the mixture is stirred at 50° C for 40 min. The reaction is then diluted with ethyl acetate and run through a silica gel plug to remove the potassium salts. The solvents are removed (low then high) vacuum to give a solid product. When purification is needed, a silica gel column is used. In this way the following compounds were prepared:

Important NMR Signals (100 MHz, CDC13)

	•	*	0	•
	Compound	BOC	C-CH ₂ -0	0-Het- <u>R</u>
	BOC-MPhe-O-Methyl nicotinate	1.44	4.95	3.875
5	BOC-HPhe-O-furan	1.44	4.8	
	BOC-HPhe-O-methyl pyrone	1.44	4.8	2.6

(d) Prep HCl - HPheCH₂2-O-Substituted heterocycle
To the BOC-PHhe CH₂-O-Substituted Aromatic (2.6mmol) in
3ml of methylene chloride was placed 8ml of 2N HCl
dioxane. The reaction was stirred about 40 min and the
resulting mixture was added dropwise to about 600ml of ether
and then filtered to give the peptide inhibitor.

EXAMPLES 12-13

Evaluation of heterocyclic-methyl, peptidyl ethers by the \underline{in} vitro inhibition of purified enzymes Cathespin B and H

Example 12: FLUOROKETONE - CATHESPIN B KINETICS

Enzyme: Cathespin B, purified from human liver, is from Enzyme Systems Products (Dublin, CA). The activity is 50 mU per ml at 30°C, in 52 mM sodium phosphate, pH 6.2, 31 mM DTT, 2.1 mM EDTA, with 0.2 mM Z-Arg-Arg-7-amino-4-trifluoromethyl-coumarin as a substrate. Specific activity is 8330 mU per mg protein. (1 mU = 1 nmol per min.)

Substrate: Boc-Leu-Arg-Arg-7-amino-4-triflouromethylcoumarin-2HBr is from Enzyme Systems Products. A 20 mM 25 solution is made in DMF and stored at -20° C.

Inhibitors: Candidate inhibitors are synthesized by

Prototek, Inc., Dublin, California. 20 mM stock solutions are made in DMF and stored at -20° C. Dilutions are made in assay buffer.

Method: The percent inhibition and the inhibitor

5 concentration at which the enzyme is 50% inhibited (IC50) are determined as follows:

Five μl of enzyme are activated by pre-incubation in three 480 μl aliquots and one 485 μl aliquot of assay buffer (50 mM potassium phosphate pH 6.2, 2 mM EDTA, 5 mM 10 DTT) on ice for 30 min. The inhibition is initiated by the addition of 5 μl of 200 μM, 20 μM, and 2 μM inhibitor each to the 480 μl aliquots. The 485 μl aliquot with enzyme is used as a control and thus receives no inhibitor. The enzyme/inhibitor mixtures are incubated 10 min. on ice 15 and assayed for cathespin B activity as follows.

Cathespin B assay: To 490 μl of pre-incubated inhibitor/enzyme mixtures in assay buffer in 0.5 ml cuvette at 37° C is added 10 μl of the substrate. Final inhibitor concentrations become 2000 nM, 200 nM, and 20 nM for the 200 μM, 20 μM and 2 μM stock concentrations, respectively. Activity is followed by release of free AFC over 5 min. (where (fluorescence units at t=6) - (fluorescence units at t=1)) with a Perkin-Elmer LS-5B spectrofluorometer (ex = 400 nm, em = 505 nm).

The percent inhibition is determined by comparing the change in fluorescence units of the three sample concentrations of inhibited enzyme to the change in fluorescence units of the control enzyme. 100 - (fl. units of sample/fl. units of control x 100) gives percent inhibition.

The IC50 is ascertained by plotting percent inhibition vs. inhibitor concentration on the log scale. The IC50 is the concentration of inhibitor (nM) at which the enzyme is inhibited by 50%.

ACTIVITY AGAINST CATHESPIN B (in vitro)

	Inhibitor (Example number)	rel. (in vitro)
	MuPhe HPhe CH ₂ -0-(methyl)pyrone (1)	112.2 nM
	MuPhe HPhe CH ₂ -O-(methyl)dihydro pyrone (2)	567.5 nM
, 5	MuPhe HPhe CH ₂ -O-(methyl)nicotinate (3)	25,100.0 nM
	MuPhe IIPhe CH ₂ -0-(3)-pyridine (4)	66.8 nM
	MuPhe HPhe CH ₂ -O-(4)-pyrimidine (5)	7,100.0 nM
	MuPhe HPhe CH ₂ -O-(2)-furan (6)	23.7 nM
	MuPhe HPhe CH ₂ -O-(2)-pyrimidine (7)	631.0 nM
10	MuPhe HPhe CH ₂ -O-proline methyl ester	031.0 IM
	N-Boc (8)	42.2 nM
	N-HCl (9)	223.9 nM
		223.3 1111

Example 13

FLUOROKETONE - CATHESPIN H KINETICS

The materials and methods were as disclosed above for Example 12 - cathespin B kinetics - except as follows:

Enzyme: Cathespin H

Substrate: HBr-Arg-7-amino-4-trifluoromethyl-coumarin

Methods: assay buffer is pH 6.8

20 <u>Activity Against Cathespin H</u>

HC1	٠	HPhe-O-(methyl)nicotinate		•	10.0	nM
HC1	•	HPhe-O-(methyl)pyrone			150.0	
		· · · · · · · · · · · · · · · · · · ·				****

EXAMPLES 14-15

Testing Heterocycle and Phenolic Leaving Groups <u>In Vivo</u>

Water solutions of inhibitor using either ethanol or DMSO

17

18

20

35 19

24

24

24

24 .

160

800

160

8000

57.40

23.30

97.50

35.9

66.8

22.8

99.6

49.2

29.6

64.0

60.2

99.2

as a cosolvent were made at 8000 nM, 800 nM and 160 nM concentrations with a minimum of solvent. Each rat was given a dose at time 0 and then individuals were sacrificed at 6hrs, 12 hrs and 24 hrs. Doses were given either by injection 5 or stomach tube.

The livers and kidneys were harvested and analyzed for Cathespin B activity. In some individuals the urine was collected at 6, 12, 24 hrs and analyzed for the presence of inhibitor. The results for Examples 14 and 15 are shown in 10 Tables 14 and 15 below.

TABLE 14

Inhibition of Cathespin B (in vivo) of MuPheHPhCH2-0

ÇH3 % Inhb 15 Paired Mean <u>Animal</u> Hrs Dose Route inh. Animal dinie 24 contr. inject. 2 24 contr. st 3 6 8000 inject. 99.6 99.6 20 6 800 inject. 59.0 43.60 51.3 5 6 160 inject. 10.3 31.80 21.0 6 st. 6 8000 89.2 90.4 7 6 800 st. 25.2 25.7 8 6 160 st. 23.9 94.50 59.2 25 9 12 8000 inject. 89.3 90.5 10 12 800 inject. 43.5 54.80 49.1 11 12 160 inject. 16.4 39.10 27.8 12 12 0008 st. 46.5 57.70 52.1 1.3 12 800 st. 9.6 11.6 30 14 12 160 st. 15.9 14.8 15 24 0008 inject. 94.9 64.70 79.8 16 24 800 inject. 40.9

The results shown in Table 14 demonstrate effective inhibition and long duration of action.

inject.

st.

st.

st.

TABLE 15

Inhibition of Cathespin B In Vivo using MuPheHPheCH20-

				,
	Time (hrs)	Dose	<u>Route</u>	%Inhibition
5	6 6 6 12	8,000 800 160 8,000	injection injection injection	63.9 46.9 35.6
10	12 12 24 24 24	800 160 8,000 800 160	injection injection injection injection injection	46.2 32.7 10.1 62.7 53.5
15	6 6 6 12 12	8,000 800 160 8,000 800	injection st. st. st. st.	42.6 79.9 54.1 61.2 83.7
20	12 24 24 24	160 8,000 800 160	st. st. st. st. st.	65.7 61.6 49.3 49.2

The results shown in Table 15 demonstrate effective, inhibition with long duration of action.

EXAMPLE 16

25 Treatment of Rheumatoid Arthritis with Mu-Phe-HPhe-O-proline methyl ester

DBA/Lac mice were injected with 200 µg of type II chick collagen emulsified in Freund's complete adjuvant on day 0 and on day 21. Mu-Phe-HPhe-O-proline methyl ester was suspended in an ethanol solution which was then diluted to 10% (aq) and administered by gavage at a dose of 10 mg/kg/day from day 21 until sacrifice at day 49. The severity of joint

inflammation was evaluated grossly at seven day intervals beginning on day 21.

The effect of oral administration of
Mu-Phe-HPhe-O-proline methyl ester on the severity of bone
lesions in adjuvant-induced arthritis was determined by
evaluating osseous mineralization, periostat proliferation,
bone erosion, joint space narrowing and osseous
fragmentation. All lesions were scored on a scale of 0
(normal architecture) to 3 (severe or marked changes).

- 10 Values calculated were mean values \pm std. error of the mean. The "bone lesion severity" values of Mu-Phe-HPhe-O-proline methyl ester treated animals were significantly (p < 0.05) lower than the values of control animals for each parameter tested.
- The effect of oral administration of

 Mu-Phe-HPhe-O-proline methyl ester on the histological
 aspects of adjuvant-induced arthritis was determined by
 evaluating inflammation, focul ulcers, tibiotarsal joint
 cartilage destruction, bone destruction and periosteal
 proliferation. Inflammation was scored on a scale of 0.4
- proliferation. Inflammation was scored on a scale of 0 (no inflammation) to 3 (severe) based on the extent of edema and cell infiltration. Focul ulcer cartilage destruction was measured as the percent of articular cartilage surfaces with focal destruction which exposed underlying subchondral bone.
- 25 Tibiotarsal joint cartilage destruction was measured as the percent of articulating surfaces with destruction of the subchondral bone. Values calculated were mean values ± 1 std. error of the mean. The "histological aspects" values of Mu-Phe-HPhe-O-proline methyl ester treated animals were
- 30 significantly (p < 0.05) lower than the values of control animals for each parameter tested.

EXAMPLE 17

Treatment of Rheumatoid Arthritis with Mu-Leu-HPhe-O-proline methyl ester

DBA/Lac mice were injected with 200 µg of type II chick collagen emulsified in Complete Freund's Adjuvant on day 0 and on day 21. Mu-Phe-HPhe-O-proline methyl ester was suspended in phosphate buffered saline and administered by gavage from day 21 until sacrifice at day 35. Doses of between 3 mg/kg/day and 25 mg/kg/day were used, with the daily dosage being held constant over time for each test. The severity of joint inflammation was evaluated grossly as seven day intervals beginning on day 21.

The effect of oral administration of

Mu-Phe-Hphe-O-proline methyl ester on the severity of bond

lesions in adjuvant-induced arthritis was determined by
evaluating osseous mineralization, periostat proliferation,
bone erosion, joint space narrowing and osseous
fragmentation. All lesions were scored on a scale of 0
(normal architecture) to 3 (severe or marked changes) Values

calculated were mean values ± 1 std. error of the mean. The
"bone lesion severity" values of Mu-Phe-HPhe-O-proline methyl
ester treated animals were significantly (p < 0.05) lower
than the values of control animals for each parameter tested.

EXAMPLE 18

Treatment of Rheumatoid Arthritis with Mu-Tyr(OMe)-HPhe-O-proline methyl ester

Rates were injected with adjuvant on day 0 and were treated with Mu-Tyr-(OMe)-HPhe-O-proline methyl ester in ground diet from the time of adjuvant injection until 30 sacrifice at day 32. Over the course of the disease, animals

were evaluated in terms of a mean clinical score, a derived series of clinically observed parameters normalized to facilitate graphical presentation. Mean paw volumes were also measured using normalized units throughout the course of the disease. At the end of the study, the animal groups were sacrificed and evaluated by X-ray analysis.

The mean clinical scores of Mu-Tyr-(OMe)-HPhe-O-proline methyl ester treated rats were significantly lower than the scores for untreated animals. Similarly, mean paw volumes were also significantly reduced. The Example demonstrates the beneficial effect of Mu-Tyr-(OMe)-HPhe-O-proline methyl ester on adjuvant-induced arthritis.

EXAMPLE 19

Effectiveness of Heterocyclic Methyl Ketones on Human and Murine Malaria Paracytes

In Vitro Effectiveness of Heterocyclic Methyl Ketones (All assays with Z-Phe-Arg-AMC)

		IC5		
. 20	0	P. falciparu (Human malar Paracyte)	ia (Mo	vinckei use malaria Paracyte)
	MuPheHPheCH ₂ -0	15 nM	:	40 nM
	MuPheHPHeCH ₂ -0-CH ₃	50 nM		500 nM
2 5	MuEhellPHeCli ₂ -0-	2 μ Μ	·	10 μΜ

EXAMPLE 20

Treatment of Gingivitis with MU-Phe-HPhe-O-furan

The effect of the inhibitor on gingival inflammation was studied by investigating its ability to prevent the 5 development of experimental gingivitis. Twenty human subjects with healthy gingiva and no periodontal disease were The subjects received oral hygiene instruction recruited. and scaling prior to baseline. The test sites were the mesibuccal crevices on the upper first and second molars and 10 premolars (bicuspids). Acrylic shields were made to cover the gingival margins of these teeth and were worn during oral hygiene to prevent brushing of the test and control sites. During the test period of three weeks the subjects were told to brush only the lower teeth and upper anteriors and to wear 15 the shields during brushing. The left side was used as the test side and the right was the control side in 10 subjects. The sides were reversed in the other 10 subjects so the subjects could act as their own controls. Thirty second GCF samples were taken prior to clinical measurements at baseline 20 and at 1, 2, 3 and 4 weeks. These were assayed for cathespins B and L-like activities. Clinical measurements of gingival index (GI), gingival bleeding index (GBI) and plaque index (PLI) were taken at test and control sites at zero, one, two, three and four weeks. Following the baseline 25 measurements the inhibitor and placebo were placed at test and control sites and sealed in with Coe-pak for a week. inhibitor and placebo were coded so that the study was blind.

The GI, GBI and PLI and cysteine proteinase levels were compared at test and control sites. It was observed that the use of Mu-Phe-HPhe-O-furan reduced all parameters tested at the test sites. Mu-Phe-HPhe-O-furan can therefore be seen to be effective in treating periodontal diseases such as

gingivitis.

In the following Examples 21-27, the active ingredient is the compound morpholine carbonyl-L-phenylalanyl-L-homophenyl alanyl methyl furanyl ether (see Example 6). However, other 5 compounds of the present invention can be substituted thereof.

EXAMPLE 21

An injectable preparation buffered to a pH of 7 is prepared having the following composition

10 Ingredients:	Active ingredient KH ₂ PO ₄ buffer	02 g 2 m1
	(0.4 M solution) KOH (1N)	q.s. to pil 7
	Water (distilled, sterile)	9.5 to 20 ml

EXAMPLE 22

An oral suspension is prepared having the following composition

20	<u>Ingredients</u>	Active ingredient fumatic acid sodium chloride methyl paraben	0.1 g 0.5 g 2.0 g 0.1 g
		granulated sugar sorbitol (70% solution)	25.5 g 12.85 g
25		Veegum K (Vanderbilt Co.) flavoring colorings distilled water	1.0 g 0.035 ml 0.5 mg , q.s. to 100 ml

EXAMPLE 23

	Ingredients	Quantity per <u>tablet, mgs.</u>
30	Active ingredient cornstarch lactose, spray-dried Maynesium stealate	25 20 153 2

EXAMPLE 24

	<u>Ingredients</u>	Quantity per tablet, mgs.		
5	Active ingredient lactose, spray-dried magnesium stearate	1.00 148		

EXAMPLE 25

,	<u>Ingredients</u>	Quantity per <u>tablet, mgs.</u>
10	Active ingredient cornstarch	200 50
	lactose magnesium stearate	145 5

The above ingredients are mixed intimately and pressed into single scored tablets.

EXAMPLE 26

15	Ingredients	Quantity per tablet, mgs.
	Active ingredient	108
	lactose	15
	cornstarch	; 25
	magnesium stearate	2

20 The above ingredients are mixed and introduced into a hard-shell gelatine capsule.

EXAMPLE 27

	<u>Ingredients</u>	Quantity per <u>tablet, mys.</u>		
25	Active ingredient lactose	150 90		

The above ingredients are mixed and introduced into a hard-shell gelatine capsule.

TOPICAL FORMULATION

:	<u>Ingredients</u>			<u>Grams</u>
5	Active compound Span 60 Tween 60 Mineral oil Petrolatum Methyl paraben			0.2-2 2 2 5 10
	Propyl paraben BHA (butylated hydroxy anisole Water	:	q.s.	0.15 0.05 0.01 100

All of the above ingredients, except water, are combined and heated to 60°C with stirring. A sufficient quantity of water at 60°C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. 100 g.

As previously indicated, the compositions of the present invention may be useful in treating disease states which are associated with cathepsins B, L, H or C. For example, the cathepsin C inhibitors of the present invention may be used to inhibit dipeptidyl peptidase I ("DPP-I") found in cytotoxic T lymphocytes, or to inhibit the processing enzyme of bobe marrow serine proteases like elastase and granzyme A.

- It is to be appreciated that vinylogous homologs of heterocycles (benzo-derivatives) would also be considered by those skilled in the art to be reactive in this context. For example, because a hydroxy pyridine derivative works as a leaving group, a hydroxyquinoline (5, 6, 7 or 8-hydroxy)

 30 would also work. Other examples of this principle of vinylogy in synthetic organic chemistry include:
 - (1) A Michael reaction is a vinylogous analog of an aldol condensation; and
- (2) An SN_2 reaction is a vinylogous analog to an SN_2 reaction.

It is also to be appreciated that because sulfur falls below oxygen in the periodic table that S may replace O in the compositions and methods of the present invention and an effective cysteine protease inhibitor would result.

Finally, it is to be appreciated that the processing of viral proteins by virally encoded proteases plays a central role in the maturation of many viruses. Examples of viruses which have been associated with cysteine proteases are polio virus (3C proteases) encephalomycarditis virsu, rhinovirus and foot-and-mouth virus. Accordingly, the compositions of the present invention are believed to be useful therapeutic agents for the treatment of viral diseases.

While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiment has been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected.

CLAIMS

What is claimed is:

Cathepsin inhibitors of the formula:

$$B-(R_3)_n-(R_2)_{in}-NH-CH-C-CH_2-O-Het$$

wherein

B is H or an amino acid blocking group for an N-terminal amino acid nitrogen;

 $^{\mathrm{R}}_{1}$ is the amino acid side chain of the $^{\mathrm{P}}_{1}$ amino acid residue;

 R_2 is the amino acid residue of the P_2 amino acid; R_3 is the amino acid residue of the P_3 amino acid; n is 0 or 1;

15 m is 0 or 1; and

Het is a hetrerocyclic leaving group; wherein the heterocyclic leaving group includes a four-, five-, six- or seven-membered ring having at least one C and at least one of N, O or S in the ring.

- 20 2. A cathersin inhibitor according to claim 1 wherein n is 0 and m is 1.
 - 3. A cathepsin inhibitor according to claim 2 wherein \mathbf{R}_2 is the residue of phenylalanyl (Phe).
- 4. A cathepsin inhibitor according to claim 3 wherein 25 R₁ is a side chain such that the P₁ amino acid residue is the residue of homophenylalanyl (MPhe).
 - 5. A cathepsin inhibitor according to claim 4 wherein B is Mu.

- 6. A cathepsin dipeptidyl peptidase inhibitor according to claim 1 wherein B = H.
- 7. A cathespin inhibitor according to claim 5 wherein Het is a benzo-fused heterocycle.
- 8. A cathespin inhibitor according to claim 5 wherein Het is dihydropyrone.
 - 9. A cathespin inhibitor according to claim 5 wherein let is hydroxyproline or a salt, or extended peptide thereof.
- $10\,.\,$ A cathespin inhibitor according to claim 5 where Het $^{10}\,$ is a pyrone.
 - 11. A cathespin inhibitor according to claim 5 wherein Het is a pyridine.
 - 12. A cathespin inhibitor according to claim 5 wherein Het is pyrimidine.
- 13. A cathespin inhibitor according to claim 5 wherein Het is a furan.
 - 14. A cathespin H inhibitor according to claim 6 wherein Het is a member of the group consisting of pyrone, pyridine, pyrimidine, furan or proline derivatives.
- 15. A cathespin H inhibitor according to claim 7 wherein Het is a pyrone, pyridine, pyrimidine, furan or proline derivative and B = H, n = 0 and m = 0.
 - 16. A composition according to claim 1, and further including a pharmaceutically acceptable carrier.

17. Cathepsin inhibitors of the formula:

$$B-(R_3)_{n}-(R_2)_{m}-NH-CH-C-CH_2-S-Het$$

5 wherein

B is H or an amino acid blocking group for an N-terminal amino acid nitrogen;

 \mathbf{R}_1 is the amino acid side chain of the \mathbf{P}_1 amino acid residue;

 R_2 is the amino acid residue of the P_2 amino acid; R_3 is the amino acid residue of the P_2 amino acid; R_3 is 0 or 1; R_4 m is 0 or 1; and

Het is a hetrerocyclic leaving group;

- wherein the heterocyclic leaving group includes a four-, five-, six- or seven-membered ring having at least one C and at least one of N, O or S in the ring.
 - 18. A cysteine protease inhibitor, comprising:
- (a) a first portion which targets a desired cysteine
 20 protease and positions the inhibitor near the thiolate anion portion of the active site of the protease;
 - (b) a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is
- 25 attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a heterocyclic leaving group;

said heterocyclic leaving group being of the formula:

wherein Het is a heterocycle having 4-7 members in the ring, with at least one of the heterocycle members being N, O or S.

19. A method of treating a patient for a medical 5 condition, said method comprising administering to the patient a therapeutically effective amount of a composition of the formula:

B-
$$(R_3)_n$$
- $(R_2)_m$ -NH-CII-C-CH₂-O-Het

wherein

10

B is H or an amino acid blocking group for an N-terminal amino acid nitrogen;

 \mathbf{R}_1 is the amino acid side chain of the \mathbf{P}_1 amino acid 15 residue;

 R_2 is the amino acid residue of the P_2 amino acid; R_3 is the amino acid residue of the P_2 amino acid; n is 0 or 1; m is 0 or 1; and

- 20 Het is a heterocyclic leaving group; wherein the heterocyclic leaving group includes a four-, five-, six- or seven-membered ring having at least one C and at least one of N, O or S in the ring.
- 20. The method of claim 19 wherein the medical condition is myocardial infarction.
 - 21. The method of claim 19 wherein the medical condition is inflammation.
 - 22. The method of claim 19 wherein the medical condition is a dystrophic disease.

- 23. The method of claim 19 wherein the medical condition is rheumatoid arthritis.
- 24. The method of claim 19 wherein the medical condition is pneumocytis carinii.
- 5 25. The method of claim 19 wherein the medical condition is schistosomiasis.
 - 26. The method of claim 19 wherein the medical condition is trypanosoma cruzi.
- $\,$ 27. The method of claim 19 wherein the medical condition 10 is trypanosoma brucei brucei.
 - 28. The method of claim 19 wherein the medical condition is Crithidia fusiculata.
 - 29. The method of claim 19 wherein the medical condition is malaria.
- 30. The method of claim 19 wherein the medical condition is periodontal disease.
 - 31. The method of claim 19 wherein the medical condition is metachromatic leukodystrophy.
- 32. The method of claim 19 wherein the medical condition 20 is muscular dystrophy.
 - 33. The method of claim 19 wherein the medical condition is cancer metathesis.
 - 34. The method of claim 19 wherein the medical condition is viral infection.

- 35. The method of claim 19 wherein the medical condition is kidney disease.
- 36. The method of claim 19 wherein the medical condition is multiple sclerosis, peripheral nervous neuropathy or the 5 like.
 - 37. The method of claim 19 wherein the medical condition is polymyositis.
 - 38. The method of claim 19 wherein the medical condition is a neurogenic disorder.
- 39. The method of claim 19 wherein the medical condition is Alzheimer's disease.
 - 40. The method of claim 19 wherein the medical condition is leukemia.
- 41. The method of claim 19 wherein the medical condition 15 is cataracts.
 - 42. The method of claim 19 wherein the medical condition is an allergy.
 - 43. The method of claim 19 wherein the medical condition is ischemia.
- 20 44. The method of claim 19 wherein the medical condition is bone resorption (osteo arthritis).
 - 45. The method of claim 19 wherein the therapeutic composition includes a pharmaceutically acceptable carrier.

1

AMENDED CLAIMS

[received by the International Bureau on 1 May 1995 (01.05.95); original claim 16 amended; remaining claims unchanged (1 page)]

- 6. A cathepsin dipeptidyl peptidase inhibitor according to claim 1 wherein B = H.
- 7. A cathespin inhibitor according to claim 5 wherein Het is a benzo-fused heterocycle.
- 8. A cathespin inhibitor according to claim 5 wherein Het is dihydropyrone.
 - 9. A cathespin inhibitor according to claim 5 wherein Het is hydroxyproline or a salt, or extended peptide thereof.
- 10. A cathespin inhibitor according to claim 5 where 10 Het is a pyrone.
 - 11. A cathespin inhibitor according to claim 5 wherein Het is a pyridine.
 - 12. A cathespin inhibitor according to claim 5 wherein Het is pyrimidine.
- 13. A cathespin inhibitor according to claim 5 wherein Het is a furan.
 - 14. A cathespin H inhibitor according to claim 6 wherein Het is a member of the group consisting of pyrone, pyridine, pyrimidine, furan or proline derivatives.
- 20
 15. A cathespin H inhibitor according to claim 7 wherein Het is a pyrone, pyridine, pyrimidine, furan or proline derivative and B = H, N = 0 and M = 0.
 - 16. A cathespin inhibitor according to claim 1, and further including a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US94/14061

7.7

	1				PCT/US9	4/14061
A. C	LASSIFICATION OF SUBJ	ECT MATTER	·			· ·
US CI	549/479, 520/200, 201, 201	4; C07D 307/02;	C07K 15/0).		
Accordin	ig to International Patent Class ELDS SEARCHED	14/18,471.			•	
B. FI	ELDS SEARCHED	incation (IPC) o	r to both na	ional classifica	tion and IPC	
U.S.	documentation searched (class 549/417; 514/460	silication system	followed by	classification :	symbols)	
	342/417, 314/400			į		
Documen	tation searched other than mini-	mum down a s				•
NONE	tation searched other than mini	mun documental	ion to the exi	ent that such do	cuments are inclu	ided in the fields searched
				•		
Electronic	data base consulted during the	international se	arch (name	£ 4.4. 1		
CAS OF	data base consulted during the		aron (name (or data base and	1, where practica	ble, search terms used)
				·		
C. DO	CID CENTER CONTRACT					
	CUMENTS CONSIDERED					
Category*	Citation of document, w	ith indication, wi	here annon-	iste of the!		T
Α	10 4 455			me, or the rela	vant passages	Relevant to claim No
^	JP, A, 163,162 (O	kada et al)	27 June	1989.		1
A						
	WO, A, 93/09135	(Heng et al) 13 Ma	/ 1993.		11
1						
- 1				•	•	1
- 1	•					
- 1						
		.1		· .	,	·
1		ले # •				
- 1				· :	i	٠,
- 1				;		_
1				7		
- 1						
1						
					•	1
					ļ	
Fughes	danmente des lista de la companya d					
Special	documents are listed in the co	ntinuation of Box	: C.	See patent f	amily annex.	
docume	aldefining the second and a second		-J-	later document pu	blished after the inter	national filing date or priority
			d	principle or theory	affect with the applicant winderlying the inventor	national filing date or priority ion but cited to understand the ition
uocume:	ocument published on or after the inte		X•	document of most	inulas — t	
cited to	nt which may throw doubts on priorit establish the publication date of and esson (as specified)	y claim(s) or which is ther citation or other	7	when the documen	r cannot be considere It is taken alone	claimed invention cannot be d to involve an inventive step
	cason (as specified) it referring to an oral disclosure, use			document of parti	cular relevance; the	laimed invention cannot be
				combined with one	Of Blom of mark	A Ancer one document #
document the prior	t published prior to the international fil ity date claimed	ing date but later than	• &•			<u>"</u>
of the actua	al completion of the internation	nal search			of the same patent far	
FEBRUAR'			Date of th	auing of the in	ternational scare	h report
			1 0	1 MAR/19	995	
	g address of the ISA/US Patents and Trademarks		Authorize	Notice /		A
PCT hington, D.C		Ŧ	1 //		11. 4	
			i cècii	IN TSANT		
mile No.	(703) 305-3230	·	Telephone			<i></i>

INTERNATIONAL SEARCH "REPORT

International application No. PCT/US94/14061

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

- I. Claims 1-6,14,16,17,19,20,45(part of each) and 7, drawn to compounds and method of treating myocardial infarction, wherein Het is furan, classified in 549/479;514/471.
- II. Claims 1-6,14,16,17,19,20,45(part of each) and 7, drawn to compounds and method of treating myocardial infarction, wherein Het is benzo-fused heterocycle, classified in various subclasses in classes 544,546 etc.
- III. Claims 1-6,14-16,17,19,20,45(part of each) and 9, drawn to compounds wherein Het is proline, classified in 548/532.
- IV. Claims 1-6,14-16,17,19,20,45(part of each) and 11, drawn to compounds wherein Het is pyridine, classified in 546/300.
- V. Claims 1-6,14-16,17,19,20,45(part of each) and 12, drawn to compounds wherein Het is pyrimidine, classified in 544/316.
- VI. Claims 1-6,14-16,17,19,20,45(part of each) and 13, drawn to compounds wherein Het is pyrone, classified in 549/417.
- VII. Claim 18, drawn to a cysteine protease inhibitor.
- VIII. Claims 19,45(part) and 21, drawn to method of treating inflammation.
- IX. Claims 19,45(part) and 22, drawn to method of treating dystrophic disease.
- X. Claims 19,45(part) and 23, drawn to method of treating rheumatoid arthritis.
- XI. Claims 19,45(part) and 24, drawn to method of treating pneumocytis carinii.
- XII. Claims 19,45(part) and 25, drawn to method of treating schistomiasis.
- XIII. Claims 19,45(part),26and27, drawn to method of treating trypanosoma cruzi and/or trypanosoma brucei.
- XIV. Claims 19,45(part) and 28, drawn to method of treating crithidia fusiculata.
- XV. Claims 19,45(part) and 29, drawn to method of treating malaria.
- XVI. Claims 19,45(part) and 30, drawn to method of treating periodontal disease.
- XVII. Claims 19,45(part) and 31, drawn to method of treating metachromatic leukodystrophy.
- XVIII. Claims 19,45(part) and 32, drawn to method of treating muscular dystrophy.
- XIX. Claims 19,45(part) and 33, drawn to method of treating cancer metathesis.
- XX. Claims 19,45(part) and 34, drawn to method of treating viral infection.
- XXI. Claims 19,45(part) and 35, drawn to method of treating kidney disease.
- XXII. Claims 19,45(part) and 36, drawn to method of treating multiple sclerosis, peripheral nervous neuropathy.
- XXIII. Claims 19,45(part) and 37, drawn to method of treating polymyosis.
- XXIV. Claims 19,45(part) and 38, drawn to method of treating neurogenic disorder.
- XXV. Claims 19,45(part) and 39, drawn to method of treating Alzheimer's disease.
- XXVI. Claims 19,45(part) and 40, drawn to method of treating leukemia.
- XXVII. Claims 19,45(part) and 41, drawn to method of treating cataracts.
- XXVIII. Claims 19,45(part) and 42, drawn to method of treating allergy.
- XXIX. Claims 19,45(part) and 43, drawn to method of treating ischemia.
- XXX. Claims 19,45(part) and 44, drawn to method of treating bone resorption.

The inventions listed as Groups I-XXX do not meet the requirements for Unity of Invention for the following reasons: Compounds wherein Het is pyrone differs significantly from compounds wherein Het is benzo-fused heterocyclic ring system, proline, pyridine, pyrimidine or furan. They are differently classified. One of ordinary skill would not treat such diverse structures as functional equivalents of each other. The mere fact there is a single similarity, i.e. the presence of a furanyl moiety, is not in itself a significant reason to render the whole embodiment obvious. The various methods of use are independent and distinct. Art which anticipate or render obvious one group is not necessarily do the same for the remaining groups. Therefore, the above groups are not so linked as to form a single inventive concept. PCT Rule 13.3, 37 CFR 1.475(d).

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ other:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.